New proteasome inhibitors in the treatment of multiple myeloma
The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S253113791830124X |
| _version_ | 1818287472011902976 |
|---|---|
| author | Vania Tietsche de Moraes Hungria Edvan de Queiroz Crusoé Rosane Isabel Bittencourt Angelo Maiolino Roberto José Pessoa Magalhães Jairo do Nascimento Sobrinho Jorge Vaz Pinto Ricardo Coutinho Fortes Eloisa de Sá Moreira Paula Yurie Tanaka |
| author_facet | Vania Tietsche de Moraes Hungria Edvan de Queiroz Crusoé Rosane Isabel Bittencourt Angelo Maiolino Roberto José Pessoa Magalhães Jairo do Nascimento Sobrinho Jorge Vaz Pinto Ricardo Coutinho Fortes Eloisa de Sá Moreira Paula Yurie Tanaka |
| author_sort | Vania Tietsche de Moraes Hungria |
| collection | DOAJ |
| description | The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly those comparing triplet regimens with standard doublet regimens, with a gain in progression-free survival accompanied by an acceptable safety profile and either similar or better health-related quality of life. New proteasome inhibitors hold the potential to fill unmet needs in multiple myeloma management regarding improvement of clinical outcomes, including delayed progression of disease in high-risk patients. This review summarizes the main pharmacological properties and clinical outcomes of these agents, and discusses their potential to change the whole multiple myeloma therapeutic landscape. Keywords: Multiple myeloma, Proteasome inhibitors, Bortezomib, Ixazomib, Carfilzomib |
| first_indexed | 2024-12-13T01:41:01Z |
| format | Article |
| id | doaj.art-ba28be5d368e447ea0952ff2b6de79ba |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-12-13T01:41:01Z |
| publishDate | 2019-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-ba28be5d368e447ea0952ff2b6de79ba2022-12-22T00:03:44ZengElsevierHematology, Transfusion and Cell Therapy2531-13792019-01-014117683New proteasome inhibitors in the treatment of multiple myelomaVania Tietsche de Moraes Hungria0Edvan de Queiroz Crusoé1Rosane Isabel Bittencourt2Angelo Maiolino3Roberto José Pessoa Magalhães4Jairo do Nascimento Sobrinho5Jorge Vaz Pinto6Ricardo Coutinho Fortes7Eloisa de Sá Moreira8Paula Yurie Tanaka9Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil; Corresponding author at: Faculdade de Ciências Médicas da Santa Casa de São Paulo, Rua Dr. Cesário Motta Jr. n° 112 Santa Cecília, 01221-020 São Paulo, SP, Brazil.Universidade Federal da Bahia, Hospital Universitário Professor Edgar Santos, Serviço de Hematologia, Salvador, BA, BrazilHospital de Clínicas de Porto Alegre, Serviço de Hematologia, Porto Alegre, RS, BrazilUniversidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, BrazilUniversidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, BrazilHospital Israelita Albert Einstein, São Paulo, SP, BrazilUniversidade Católica de Brasília, Brasília, DF, BrazilEvidências – Kantar Health, São Paulo, SP, BrazilEvidências – Kantar Health, São Paulo, SP, BrazilTakeda Pharma, São Paulo, SP, BrazilThe treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly those comparing triplet regimens with standard doublet regimens, with a gain in progression-free survival accompanied by an acceptable safety profile and either similar or better health-related quality of life. New proteasome inhibitors hold the potential to fill unmet needs in multiple myeloma management regarding improvement of clinical outcomes, including delayed progression of disease in high-risk patients. This review summarizes the main pharmacological properties and clinical outcomes of these agents, and discusses their potential to change the whole multiple myeloma therapeutic landscape. Keywords: Multiple myeloma, Proteasome inhibitors, Bortezomib, Ixazomib, Carfilzomibhttp://www.sciencedirect.com/science/article/pii/S253113791830124X |
| spellingShingle | Vania Tietsche de Moraes Hungria Edvan de Queiroz Crusoé Rosane Isabel Bittencourt Angelo Maiolino Roberto José Pessoa Magalhães Jairo do Nascimento Sobrinho Jorge Vaz Pinto Ricardo Coutinho Fortes Eloisa de Sá Moreira Paula Yurie Tanaka New proteasome inhibitors in the treatment of multiple myeloma Hematology, Transfusion and Cell Therapy |
| title | New proteasome inhibitors in the treatment of multiple myeloma |
| title_full | New proteasome inhibitors in the treatment of multiple myeloma |
| title_fullStr | New proteasome inhibitors in the treatment of multiple myeloma |
| title_full_unstemmed | New proteasome inhibitors in the treatment of multiple myeloma |
| title_short | New proteasome inhibitors in the treatment of multiple myeloma |
| title_sort | new proteasome inhibitors in the treatment of multiple myeloma |
| url | http://www.sciencedirect.com/science/article/pii/S253113791830124X |
| work_keys_str_mv | AT vaniatietschedemoraeshungria newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT edvandequeirozcrusoe newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT rosaneisabelbittencourt newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT angelomaiolino newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT robertojosepessoamagalhaes newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT jairodonascimentosobrinho newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT jorgevazpinto newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT ricardocoutinhofortes newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT eloisadesamoreira newproteasomeinhibitorsinthetreatmentofmultiplemyeloma AT paulayurietanaka newproteasomeinhibitorsinthetreatmentofmultiplemyeloma |